AONC: aoncology.com Company Value to Net Income

American Oncology Network, Inc. - graphic logo of issuer AONC

American Oncology Network (AONC) is aggressively capturing the regional cancer center segment by optimizing drug costs through the acquisition of private practices. This market valuation chart reflects a value of -1.00. The business relies on an integrated approach, combining pharmacies and diagnostics to stabilize profits. However, expansion is complicated by the war for talent and pressure from healthcare behemoths.

Price to Earnings Ratio: AON (AONC) for 02/21/2024 - 08/04/2024

Comprehensive metric breakdowns and analytics for American Oncology Network Inc (AONC)

Summary company analysis:AONC, American Oncology Network Inc
Flagship merchandise of American Oncology Network, Inc.

Optimizing non-clinical processes through outsourcing enhances the operational efficiency of American Oncology Network (AONC). The P/E ratio measures the cost per unit of profit, determining the extent to which an investor is overpaying for an asset. By analyzing the P/E ratio dynamics of American Oncology Network (AONC), one can identify the sustainability of the long-term trend. A decline in this metric signals either undervaluation or rising risks, while a stable figure confirms the strength of market capitalization and the reliability of the business model.

Analysis of competing companies

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme Inc.)|RVMD (RevMed) - Company Value to Net Income|P/E Multiple AAPG (ascentage.com)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis Corp (PSNL) - Price to Earnings Ratio|Erasca Corp - Company Value to Net Income|DCTH (Delcath Systems Inc) - P/E Multiple|Market Cap to Earnings Y-mAbs Therapeutics, Inc. YMAB|P/E Multiple AURA|Price to Earnings Ratio Candel Therapeutics, Inc. CADL|P/E Multiple ARAY (Accuray, Inc.)|SELLAS Life Sciences - Price to Earnings Ratio|ACTU: Price to Earnings Ratio|Citius Oncology, Inc. - Market Price to Net Income Ratio|HURA (TuHURA Biosciences) - Price to Earnings Ratio|TARA: Market Price to Net Income Ratio|Price to Earnings Ratio FATE|WHWK: Company Value to Net Income|Price to Earnings Ratio TCRX (TScan Therapeutics Inc)|Business Payback Period Champions Oncology Inc|P/E Multiple XBIT (XBiotech Inc.)|Company Value to Net Income CVM|OS Therapies Inc. - P/E Multiple|RADX - P/E Multiple|ARTV: P/E Multiple|ANL: Market Price to Net Income Ratio|Price to Earnings Ratio VERU|TPST: Company Value to Net Income|Price to Earnings Ratio xiliotx.com (XLO)|Renovaro - Price to Earnings Multiple|Price to Earnings Ratio Mural Oncology MURA|KAPA - Price to Earnings Ratio|OKUR - Price to Earnings Ratio|GDTC - P/E Multiple|Curis, Inc. (CRIS) - Price to Earnings Ratio|Price to Earnings Ratio Apollomics, Inc.|Price to Earnings Ratio THAR|Price to Earnings Multiple ADVB (Advanced Biomed)|Price to Earnings Ratio GNPX (Genprex, Inc)|CLDI: Market Cap to Net Income|Price to Earnings Ratio sunshinebiopharma.com SBFM|XBIO - Price to Earnings Ratio|SLRX: Price to Earnings Ratio|Purple Biotech - Market Price to Net Income Ratio|BeOne Medicines (BGNE) - Price to Earnings Ratio|Checkpoint Therapeutics, Inc (CKPT) - P/E Multiple|Price to Earnings Ratio Elevation Oncology, Inc.|ICAD: Company Value to Net Income|Price to Earnings Ratio ikenaoncology.com (IKNA)|Price to Earnings Ratio NTBL (Notable Labs, Ltd.)|P/E Multiple VIRX (viracta.com)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV